Cochrane · systematic review · CD012069
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
Storebø, OJ, Pedersen, N, Ramstad, E, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
7
No studies
2
Included studies
NR
No studies 2 · 22.2%Ungraded 0 · 0%Very low 7 · 77.8%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Methylphenidate for children and adolescents aged 18 years and under with attention deficit hyperactivity disorder (ADHD): adverse events
Population: children and adolescents aged 18 years and under diagnosed with ADHD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Comparative studies | no estimate extracted | NR | No studies |
Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated | RR 1.36 [1.17, 1.57] | 2 studies · 72005 participants | Very low Downgraded: risk of bias |
Non‐comparative studies | no estimate extracted | NR | No studies |
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) | no estimate extracted | 51 studies · 162422 participants | Very low Downgraded: risk of bias |
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) | no estimate extracted | 7 studies · 1173 participants | Very low Downgraded: risk of bias |
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) | no estimate extracted | 22 studies · 3708 participants | Very low Downgraded: risk of bias |
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) | no estimate extracted | 49 studies · 13978 participants | Very low Downgraded: risk of bias |
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) | no estimate extracted | 37 studies · 7142 participants | Very low Downgraded: risk of bias |
Withdrawal of methylphenidate for unknown reasons Measure by: proportion of participants withdrawn from treatment Average study duration (range): 6.13 months (1 day to 36 months) | no estimate extracted | 57 studies · 8340 participants | Very low Downgraded: risk of bias |